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ABSTRACT
MANIPULATION OF THE IMMUNE SYSTEM TO INCREASE ANTI-TUMOR
RESPONSE AGAINST OVEREXPRESSED HER-2/NEU PROTEIN
By
Horacio Soto
Current treatments for cancer include surgery, radiation, and chemotherapy.
Although these treatments have improved over the past two decades, prognosis for
patients with malignancies remains poor. Immunotherapy appears to be a promising
treatment option for cancer patients. In immunotherapy, a patient’s immune system is
used to elicit an immune response against specific antigens found on tumor cells.
Dendritic cells (DC) as professional antigen-presenting cells (APC) play a vital role in
activation of CD8+ TC cells via class I major histocompatobility complex (MHC). This
interaction is crucial in developing a cytotoxic response against malignant cells.
The purpose of this study was to determine how effective DC would be in
activating a CD8+ T cell, via an MHC class I pathway, when pulsed with either soluble
Her-2/neu or Her-2/neu bound to polystyrene beads. Additionally, the maturity of the DC
were compared to determine how immature versus mature DC would effect activation.
The use of mature DC pulsed with Her-2/neu coated beads resulted in increased antigen
specific activation of CD8+ T cell at much lower concentrations when compared to
immature DC tested in the same manner. Activation using Her-2/neu coated beads was
superior to soluble Her-2/neu or ovalbumin alone. This study illustrates the importance of
DC maturity as well as the mode of antigen delivery required to elicit a specific cytotoxic
immune response. The results of this study indicate a promising outlook in developing
specific immunotherapies for malignancies and thus warrant further investigation.
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INTRODUCTION
Background
The American Cancer Society defines cancer as “a group of diseases
characterized by uncontrolled growth and spread of abnormal cells” (American Cancer
Society, 2009). Death may be an end result if the spread of abnormal cells is not
controlled. Cancer may be caused by either external factors (tobacco, chemicals,
radiation and infectious organisms) or internal factors (inherited mutations, hormones,
immune conditions, and metabolism caused mutations), these factors may even act
together or in series to promote carcinogenesis.
It is estimated that 1,479,350 new cancer cases will be diagnosed in 2009, of these
192,370 new cases of invasive breast cancer cases are expected to occur among US
women (American Cancer Society, 2009). Breast cancer is the most commonly
diagnosed cancer in women. The American Cancer Society has estimated that in 2009
breast cancer will account for 40,610 deaths, with 40,170 of these individuals being
women, and 440 of them being men (American Cancer Society, 2009). The most current
data indicates that the mortality in women as a result of breast cancer has dropped
approximately 2.2% per year from 1999 to 2005 in all women, with the greatest decreases
seen in women younger than 50 years of age. Despite of all the advancements in
screening and treatment, breast cancer still remains the second leading cause of death in
woman (American Cancer Society, 2009). The current five year relative survival rate for
localized breast cancer, breast cancer that has not spread to surrounding tissue or organs
is reported to be approximately 98%. In patients whose tumors have metastasized, the
survival rate decreases dramatically to only 27% (American Cancer Society, 2009). The
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survival rate for all breast cancer groups decreases past five years, with a ten year
survival rate of 81%, compared to an overall breast cancer survival rate of 89% at five
years (American Cancer Society, 2009).
The early onset of breast cancer can be detected by mammograms. Mammograms
can usually detect abnormalities before they can be detected by either the woman or a
health care provider. The American Cancer Society’s screening guide lines recommends
yearly mammograms starting at age 40. If the patient declines to obtain the yearly
mammogram abnormalities and complications may develop. If cancer is left
undiagnosed it can grow to the point where physical signs and symptoms can be
observed. The signs and symptoms may include a breast lump, thickness, swelling,
distortion, or tenderness; it is also common to see skin irritation or dimpling, nipple pain,
scaliness, ulceration, retraction or spontaneous discharge (American Cancer Society,
2009). Breast pain has been observed in some cases, but usually it is due to other
conditions and it is not generally related to breast cancer.
The risk of being diagnosed with breast cancer increases with age. The most
important factors that increase the risk of this type of cancer in women include inherited
genetic mutations, a family history of breast cancer, biopsy confirmed hyperplasia,
especially atypical hyperplasia, and the tissue density of the breast (a mammographic
measurement used to determine the amount of glandular tissue relative to fatty tissue
within the breast) (American Cancer Society, 2009).
It has been reported that mutations, specifically mutations that occur on
chromosome 17 are associated with HER-2/neu positive breast cancer. HER-2/neu
positive breast cancers account for 20-30% of all reported cases and are linked to poor
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prognosis because they do not respond to conventional treatment. The mutations that
cause HER-2 overexpression occur on the long arm of chromosome 17 (17q21) which
encodes for a 185 KDa cytoplasmic membrane glycoprotein that is involved in tyrosine
kinase signal transduction for epithelial cell proliferation and known as either HER-2/neu
(Human Epidermal Growth Factor Receptor 2/neu) proto-oncogene or c-erbB-2 (RefSeq
NM_001005862) (Schippinger et al., 2004). The abnormal HER-2/neu gene contains
additional exons at the 5’ end and lacks an alternate 5’ noncoding exon, when compared
to the normal gene. HER-2/neu gene amplification or receptor overexpression has been
reported in approximately 20-30% of human primary breast cancers and in over 90% of
cases, HER-2/neu oncogene overexpression may be a result of HER-2/neu gene
amplification (Schippinger et al., 2004; Wang, Saboorian, Frenkel, Hyman, Gokaslan, &
Ashfaq, 2000). This amplification causes an increase in the number of gene copies in the
cell, resulting in an increased concentration of the subsequent mRNA and eventually an
increase in HER-2/neu oncoprotein. Evaluating the status of HER-2/neu has gained
importance in the clinical assessment of patients with breast cancer, especially since
HER-2/neu overexpression or amplification in node positive cases has been linked to
poor prognosis, including short-ended disease free periods and decreased overall survival
time, possibly due to a resistance to conventional therapy (Schippinger et al., 2004).
Determining the status of HER-2/neu in patients with breast cancer enables healthcare
providers to better predict the response of the patient to specific treatments and may
guide the course of treatment the patient will receive.
Treatment for breast cancer may vary depending on tumor size and tumor
characteristics. Treatments may include two or more methods in combination. Surgery is
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one of the options healthcare providers and patients consider when treating breast cancer.
The surgical options include procedures such as lumpectomy (removing only the tumor),
mastectomy (removal of the entire affected breast), as well as excising some of the
axillary lymph nodes, which are used to obtain precise information regarding the stage of
the disease. Other treatments include radiation therapy, chemotherapy, and hormone
therapy (American Cancer Society, 2009). Patients who are diagnosed with HER-2/neu
positive breast cancer may be treated with the immunotherapeutic agent trastuzumab
(Herceptin). Herceptin is a humanized anti-HER-2/neu monoclonal antibody which can
be used not only for HER-2/neu positive breast cancer but also for reoccurring breast
cancer or progression during chemotherapy (Selvarajan, Bay, Chng, & Tan, 2004).
Immunotherapy is a newer concept that is being considered as a treatment option
against many different types of cancer. The basis of immunotherapy is stimulating the
patient’s immune system in order to initiate an attack against malignant tumor cells. An
ideal immunotherapy for cancer would be tumor-specific, easy to construct, and safe
when it is administered to patients. It would allow patients diagnosed with a tumor to be
treated based on specific proteins that are expressed by the tumor, allowing for a sitespecific cytotoxic response. Through the use of antigen presenting cells, specifically
dendritic cells (DC), a cytotoxic response may be initiated against a specific tumor
allowing for little to no undesirable side effects.
Dendritic cells are highly specialized professional antigen-presenting cells (APC)
that have unique morphological and molecular properties enabling them to be efficient
initiators and modulators of the immune system. They are found in all tissues and in the
blood in extremely small numbers and they make up about less than 0.1% of all the
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circulating leukocytes. Dendritic cells are capable of internalizing foreign matter by
micropinocytosis and phagocytosis. Upon internalization of foreign matter dendritic cells
can process antigen into short peptides that can be presented on either major
histocompatability complex (MHC) I or II (Banchereau & Steinman, 1998).
The term Dendritic cell (DC) was proposed by Steinman and Cohn (1973), where
they reported the morphology and the sites in which these cells could be found. The
authors went into great detail in describing the cell’s morphology: they describe them as
having, “a large nucleus, refractile, contorted in shape, contain small nucleoli (usually
two); abundant cytoplasm, processes that varied in length and width and the cells contain
many large spherical mitochondria”. Based on their findings Steinman and Cohn
reported that in mice, the spleen was the most abundant source of dendritic cells,
comprising approximately 1.0-1.5% of the total nucleated cell population. They also
reported that primary lymphoid organs such as Payers patches and lymph nodes
contained only a small number of dendritic cells, while the other primary lymphoid
organs, bone marrow, intestine and thymus, did not contain dendritic cells.
In 1986, Bowers and Berkowitz conducted a study where they were able to
determine that DC were not detectable in fresh preparations in bone marrow cultures.
They did however notice that DC arise from bone marrow cultures after short term
culturing, indicating that DC originate from bone marrow. They also observed that DC
originated from a precursor cell within bone marrow, which had a number of
distinguishable properties that did not resemble DC in any way. It is now known that a
number of cells that comprise the immune system are made in the bone marrow from
pluripotent hematopoietic stem cells through a process known as hematopoiesis. All
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blood cells are derived from pluripotent hematopoietic stem cells, these cells can divide
without differentiation to renew themselves, and they can also differentiate into a number
of more mature cells, such as DC. The differentiation of pluripotent hematopoietic stem
cells is regulated by cytokines (Thomas & Lipsky, 1996). Depending on the cytokine
signal received, pluripotent hematopoietic cells in the bone marrow will differentiate into
a variety of mature cell types. It has been shown that pluripotent hematopoietic stem cells
differentiate into DC in the presence of granulocyte macrophage-colony stimulating
factor (GM-CSF), which has been reported to play an important role in the development
and maturation of DC (Kampgen et al., 1994).
Dendritic cells are found in an “immature” and “mature” state. The “maturation”
state is a functional term given to DC in order to describe them in a given moment and
site that describes a preference for either the ability to process antigens or the ability to
migrate and activate T cells. Subsequent data has shown that the majority of DC reside
in primary lymphoid organs, such as the spleen and thymus, as well as in the skin and the
mucosa. Once immature DC have encountered and internalized antigens they undergo
changes (“maturation”) including down regulation of protein, increased antigen
processing capacity and ability to migrate to regional lymph nodes where antigenicepitopes are presented to T lymphocytes (Inaba et al., 1992).
Studies have shown that the addition of granulocyte macrophage colony
stimulating factor (GM-CSF) and tumor necrosis factor-alpha (TNF-α) to a culture
containing human hematopoietic progenitor cells, stimulated the growth of a subset of
monocytes and cells that resembled DC, functionally and phenotypically. When the
human hematopoietic progenitor cells were grown in the presence of GM-CSF alone,
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there was an increase in the quantity of monocytes within the culture and no increase in
DC proliferation was observed. The cultured DC grown in the presence of GM-CSF and
TNF-α were found to be as active as other purified DC. This was a great success, in that
it shows that human DC are derived from hematopoietic progenitor cells, and that these
cells can also be used to conduct immunological studies (Koch, Heufler, Kampgen,
Schneeweiss, Bock, Schuler, 1990). However, recent studies have shown that in mice,
GM-CSF alone, is sufficient for the proliferation and differentiation of DC from their
hematopoietic progenitor cell precursors (Thomas & Lipsky, 1996). Inaba et al. (1992)
described a method in which mouse DC can be cultured from bone marrow; this method
requires the depletion of lymphocytes, macrophages, and granulocytes and the culturing
of the remaining cells in GM-CSF for seven days.
Dendritic cells have been recognized as the initiators and the modulators of the
immune system. Dendritic cells are effective educators of B and T lymphocytes. Unlike
B cells that can become activated by antigen complexing with their cell surface receptors,
T cells require antigen to be processed and presented to them by antigen processing and
presenting cells (Banchereau & Steinman, 1998). Dendritic cells are professional antigen
processing and presenting cell and have a unique ability to initiate an immune response in
vivo (Caux et al., 1996). In vitro incubation of DC with tumor lysates or transfection of
genes encoding for tumor-associated antigen results in the generation of DC that activate
T-cells. Dendritic cells express high levels of antigen-presenting molecules (MHC class I
or II), which enables the internalization and amplification of a specific immune response
to target antigens (Caux et al., 1996).
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Dendritic cell vaccination experiments in animals have prevented growth of
transplanted cancer cells and reduced the size and growth of established tumors
(Mayordomo et al., 1995). In order for the immune system to attack cancer cells or
tumors, antigens must first be presented via the MHC class I pathway to cytotoxic T cells
(TC cell) for activation (Diegel, Chen, Laus, Graddis, & Vidovic, 2003). Dendritic cells
loaded with tumor proteins are believed to be capable of presenting antigens through both
the MHC class I and class II pathways. The fact that dendritic cells can process
exogenous antigens and present them in the MHC class I pathway, indicates that DC can
carry out a process that has been termed cross-priming or cross-presentation. The
presentation of antigens in the MHC class I pathway is key in activating cytotoxic T cells.
It has been shown that only lymphoid dendritic cells cross-present antigens, and therefore
these cells are essential for the initiating of a cytotoxic T lymphocytes (CTL) response
(den Haan, Lehar, & Bevan, 2000). Therefore, isolation of dendritic cells from a
lymphoid organ, and subsequent loading of exogenous antigen (i.e. tumor proteins) must
be completed in vitro before they can cross-present and initiate the differentiation of
naïve CD8 T cells into CTL.
Dendritic cells have many properties that enable them to have great surveillance
capabilities. By introducing proteins to the immune system that are specific to either
tumors or tumor cells it may be possible to initiate early surveillance against tumors or
tumor cells that would normally be overlooked because in early tumorgenesis the cells
are not recognized as foreign. Developing an effective way to introduce tumor associated
antigens into DC and using their ability to cross-present and activate CTLs, a protective
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and therapeutic anti-tumor treatment may be developed allowing for patients to have an
additional treatment option to consider when dealing with the discovery of a tumor.

Experimental Design & Objectives
The purpose of this study was to determine the effect that peptide-loaded DC will
have when co-cultured with a T cell hybridoma, B3Z, which is able to express βgalactosidase when activated via an MHC class I pathway. The DC were loaded with
either soluble protein or protein attached to microspheres. Given that APC specifically
DC, are believed to take up particulate matter more efficiently than soluble protein, we
hypothesized that attaching the proteins to the microspheres allowed for a greater up-take
of protein and thus a greater immune response. This immune response was measured by
using a T cell hybridoma that is activated by SIINFEKL, an eight amino acid sequence
from chicken ovalbumin. This sequence was incorporated into the amino acid sequence
of a recombinant form of HER-2 protein, referred to as EVI.

MATERIALS and METHODS
Production of Colonies
Escherichia coli transfected with the plasmid vector pTriex (Novagen) into which
EVI DNA had been cloned was obtained from Dendreon Corporation of Seattle,
Washington. These cells produced a recombinant protein known as HER-2/neu. The
acronym EVI stands for External - OVA – Internal, where the external and internal refers
to the extracellular and intracellular portions of the HER-2/neu receptor. The OVA
portion within EVI refers to SIINFEKL, amino acid residues 257-264 of chicken
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ovalbumin which are recognized by the B3Z CD8+ T cell hybridoma. The recombinant
protein was also engineered with a six-histidine tag, which was used to isolate the protein
during the purification process. Using sterile technique, E. coli cells were streaked on a
plate containing LB agar with chloramphenicol (34mg/ml) and carbenicillin (100mg/ml).
The plate was incubated at 37°C for 48 hours. Archive plates were sealed in parafilm and
stored at 4°C for future use.

Culture Cultivation
From the archive plate, a single isolated and viable bacterial colony was obtained
on the end of a sterile toothpick and used to inoculate a 25 ml volume of LB (LuriaBertani) broth with carbenicillin (100mg/ml) and chloramphenicol (34mg/ml). This
“overnight” culture was placed on a shaker at 200 rpm in a 34oC incubator until the
solution was cloudy. From this culture, 1 ml was removed and added to a 2 L Erlenmeyer
flask containing 500 ml LB broth with antibiotics, as previously described. A second
flask was prepared using the same method to produce a total of 1 L of culture. Flasks
were incubated at 34oC while shaking at 200 rpm until cloudy. A spectrophotometer set
to 600 nm absorbance was used to find the optical density (OD) of the broth. When the
Abs600 reached 0.5, which is equal to 5 x 105 colony forming units/ml, 1mM IPTG
(Isopropyl β-D-1-thiogalactopyranoside) was added to the culture and allowed to
continue incubating for an additional two hours. These cultures were divided into 4-500
ml Nalgene centrifuge bottles and centrifuged using the Sorvall RC-5B Plus centrifuge at
10,000 g using the SLA-3000 rotor at 4°C. Pellets from 500 ml of broth were combined
and stored at -20°C.

10

Isolation and Purification of Inclusion Bodies
The combined bacterial pellets were removed from the freezer and allowed to
thaw. Cells were thoroughly resuspended using 40 ml Buffer A (50 mM Tris, 25%
Sucrose, pH 8.0) per bottle. The cells were then lysed by addition of 100 ml of Buffer B
(20 mM Tris, 100 mM NaCl, 1% Deoxycholate, 1% Triton X-100, 0.3mg/ml Lysozyme,
pH 8.0). The suspension was shaken for 10 minutes at room temperature using horizontal
shaker. Following the incubation, 0.2 µl/ml Benzonase and 1mM MgCl2 were added to
each bottle. The suspension was allowed to stir for an additional five minutes, a marked
decrease in viscosity was noted. The samples were centrifuged at 20,000 g for 15 minutes
at 4°C and supernatant was discarded. Pellets were resuspended in 25 ml of Buffer C (20
mM Tris, 100 mM NaCl, 1% Triton X-100) and additional Buffer C was added to bring
the total volume to 200 ml per bottle.
Following centrifugation at 20,000 g for 10 minutes, 4°C, the supernatant was
discarded. This resuspension-centrifugation step involving Buffer C was repeated three
additional times. Upon completion of the centrifugation step, the pellets were
resuspended in 200 ml per bottle of Base Buffer (20 mM Tris, 100 mM NaCl) and spun at
20,000 g for 10 minutes at 4°C, and the supernatant was discarded. The pellets were then
resuspended in 25 ml Base Buffer and centrifuged at 20,000 g, 10 minutes, 4°C, after
which the supernatant was removed and inclusion bodies were stored at -20°C.

Solubilization of Inclusion Bodies
Inclusion bodies samples were removed from -20°C and were allowed to thaw at
room temperature. Once the samples had thawed they were resuspended in 20 ml
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solubilization buffer (20 mM Tris, 6M Guanidine HCl, 0.5 M NaCl, 10 mM imidazole,
pH 8.0) with 5mM β-mercaptoethanol. The pellets were vortexed vigorously to ensure
resuspension of the pellet. Tubes were then incubated at room temperature for 55 minutes
while shaking. Following incubation the tubes were centrifuged at 10000 x g, 10 minutes,
4°C. The solubilized inclusion bodies (supernatant) were saved, and passed through a
0.22 µm cellulose acetate filter and stored at -20°C.

FPLC Isolation of EVI Recombinant Protein
Recombinant protein was purified by passing over a 5 ml Hitrap chelating
column (GE Healthcare) which was loaded with NiSO4 (100mM) following the
manufacturers protocol using FPLC. The pumps were washed with sterile H2O, then
separately washed: pump A was filled with solubilization buffer (20 mM Tris, 6M
Guanidine HCl, 0.5 M NaCl, 10 mM imidazole, pH 8.0), and pump B was filled with
elution buffer (20 mM Tris, 6 M Guanidine HCl, 0.5 M NaCl, 300 mM Imidazole, pH
8.0).
In order to ensure the column was free of unwanted protein a mock elution was
performed using elution buffer. While the mock elution was underway, 10 ml of protein
sample was injected via syringe into a 10 ml loop. The loading of protein to the loop was
performed a second time in order to bring the total sample size loaded on the Ni-column
to 20 ml. To prevent the loss of any protein the fraction collector was set to collect 10 ml
per tube at the time the protein was injected into the column. The fractions were saved
and labeled “flow thru”. After the second injection of protein into the loop, 20 ml of
buffer was pumped through the column before the fraction collector was reset to 1 ml per
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tube. The column was then flushed with solubilization buffer (20mM Tris, 6 M
Guanidine HCl, 0.5 M NaCl, 5mM β-mercaptoethanol, 10 mM imidazole, pH 8.0),
samples were saved from this elution and labeled 20 mM. The final rinse for the column
was performed with elution buffer (20 mM Tris, 6 M Guanidine HCl, 0.5 M NaCl, 300
mM Imidazole, pH 8.0); these samples were collected, pooled, and labeled 300 mM. The
samples were then combined based on the absorbance values (Fig. 1). Upon completion
EDTA (2 µM) was added to the 300 mM sample. The samples were stored at -20°C. The
purity of the sample was determined by performing sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE) in NuPAGE® 4-12% Bis-Tris Pre-Cast
gels (Invitrogen). A standard BCA assay was performed in order to determine the
approximate concentration of the 300 mM sample. The standard curve was prepared by
performing serial dilutions of 1mg/ml of bovine serum albumin (BSA) to phosphate
buffered saline (PBS), (0 mg/ml BSA).
Refolding of Isolated Recombinant Protein
The 300 mM imidazole samples were removed from the -20°C and allowed to
thaw completely. Just prior to refolding, DTT was added to 2 mM; the concentrations of
the samples were determined using the extinction coefficient for HER-2 with the
incorporated ovalbumin (SIINFEKL), using the Shimadzu spectrophotometer at 280 nm
(extinction coefficient for HER-2 + SIINFEKL measured at 280 nm in water was 41715
M-1 cm-1). The sample was then prepared as follows: 2µl of DTT were added to 500 µl of
the protein sample; to this, 498 µl of buffer (20 mM Tris stock, 6 M Guanidine HCl, 0.5
M NaCl, and 2 mM EDTA) was added, and the entire solution was incubated at 37°C for
30 minutes. Following the incubation, additional buffer was added to bring the total
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volume to 15 ml, and this solution was dialyzed using a Pierce Slide-a-Lyzer dialysis
cassette with a MWCO of 10 kDa.
The protein sample was then dialyzed against renaturation buffer (100 mM Tris
stock, 0.5 M L-arginine, 2 mM EDTA, pH 8.0, with 2.5 mM reduced glutathione and 0.5
mM oxidized glutathione added just prior to use) for 13 hours at 4°C with constant
spinning to ensure circulation of buffer. This was replaced after the 13-hour period with
fresh 4°C renaturation buffer, and allowed to stand for an additional 9 hours. Afterwards,
the buffer was replaced with 1x PBS and left for 3 days at 4°C.

Forced Protein Adsorption on Polystyrene Microspheres
The polystyrene microspheres used in this study were purchased from Bangs
Laboratories Inc. The manufacture’s protocol for forced adsorption was followed. A 7 ml
bead and adsorption buffer (PBS: 10.4 mM dibasic potassium phosphate and 1.8mM
monobasic sodium phosphate) solution was prepared by combining 0.7 ml of beads and
6.3 ml of adsorption buffer. The pH of the solution being used for each individual protein
was adjusted according to the iso-electric point (pI) for that specific protein (pI of EVI =
5.63 and pI of OVA= 5.19) used in the study. Based on the specifications and the
information provided by the manufacturer the microsphere surface saturation was
determined to be between 720 μg – 2400 μg of protein. The beads and the adsorption
buffer were placed into a flat-bottom test tube and stirred for 10 minutes to ensure proper
mixture of the solution. The desired amount of protein was added after 10 minutes of
stirring and was allowed to continue stirring for an additional 30 minutes at room
temperature. Upon completion of the 30 minute incubation, a sample was taken and
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viewed under the microscope. If agglutination was seen, the sample was then incubated at
37oC for an additional 30 minutes. If no agglutination was seen, the samples were then
incubated at 4oC overnight while stirring. The following day, the samples were removed
from the stir plate, and the beads were allowed to settle for 24-48 hours. The supernatant
was then tested by performing a BCA assay (Pierce) in order to determine the amount of
free protein that was not attached to the microspheres.

Isolation of Dendritic Cells from a Secondary Lymphoid Organ
The experiments involving the use of vertebrate animals were all conducted with
the approval of Northern Michigan Universities, Institutional Animal Care and Use
Committee.
A female H2-Kb positive C57BL/6 mouse was euthanized by cervical dislocation,
and the spleen was removed using aseptic technique. The spleen was placed in a Petri
dish containing 10 ml of complete RPMI-1640 (RPMI-1640, supplemented with 100 ml
FBS, 10 ml kanamycin, 10 ml nonessential amino acids, 10 ml sodium pyruvate, 10ml
HEPES, 10 ml β-mercaptoethanol, sterile filtered using a 0.22 μM filter) . In a class II
biosaftey cabinet, two sterilized, frosted end microscope slides were rinsed in sterile PBS
and used to homogenize the spleen using the rough side of the frosted end of the slides.
The grinding of the spleen was done over a Petri dish containing the 10 ml of complete
RPMI-1640. The cells were collected and placed in a 15 ml centrifuge tube. The Petri
dish and microscope slides were then rinsed with 5 ml of media which was added to the
15 ml centrifuge tube. The sample was centrifuged at room temperature for 5 minutes at
400 g. The media was then removed and the cell pellet was resuspended in 1 ml of red
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blood cell lysing buffer (Sigma-Aldrich) per spleen, and incubated for 1 minute at room
temperature. An additional 14 ml of media was then added and the sample was
centrifuged as before. The cells were resuspended in 7 ml of complete RPMI-1640 per
spleen and transferred to a 25 ml cell culture flask. The cells were then incubated at 37o,
5% CO2, for 2-4 hours. Once incubation was complete the media and non-adherent cells
were removed by aspiration, and 10 ml of complete RPMI-1640 was added to the flask.
The cells were harvested by using a 25 cm cell scraper and scraping the flask. The cells
were collected and placed in a 15 ml centrifuge tube were they were centrifuged and
resuspended in 5 ml of complete RPMI-1640 per spleen.

Preparation of Bone Marrow Derived Dendritic Cells
A plasmacytoma cell line (J558) which had been transfected with the murine GMCSF gene cloned into a mammalian expression vector was allowed to thaw at room
temperature under a sterilized class II biosaftey cabinet. The J558 cells (1 ml) were then
transferred into a 15ml centrifuge tube using sterile technique with an additional 9 ml of
IMDM media (Invitrogen Corporation, Carlsbad, CA). The tube was centrifuged for 5
minutes at 1250 rpm. The supernatant was aspirated and the wash steps were repeated
two additional times. The cells were transferred into a 25 ml cell culture flask and 50
mg/ml (37.5 μl of antibiotic to 1 ml of IMDM 10% FBS) of Geneticin (Invitrogen
Corporation, Carlsbad, CA) was added to the culture flask and incubated at 37oC, 5%
CO2 for 48 hours. On day two the media was replaced using IMDM 10% FBS (Invitrogen
Corporation, Carlsbad, CA) and 50 mg/ml of Geneticin, by centrifugation for 5 minutes
at 1250 rpm, aspirating the old media and replacing it with the new media for an
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additional 48 hours. Cells were observed and divided when necessary. On day six, the
cells were collected by centrifugation as before and resuspended in 10ml of IMDM 10%
FBS and placed into a new 25 cm2 cell culture flask and incubated for an additional 48
hours. When the media was replaced, the supernatant was collected and stored at 4oC to
be used later as a source of GM-CSF necessary for the differentiation of DC from
hematopoietic stem cells found in bone marrow.
Bone marrow was collected using sterile instruments and technique from female
C57 BL/6 mice. The mice were euthanized by cervical dislocation. They were then
transferred to the laboratory were they were wetted with 70% EtOH. Incisions were made
to expose and remove both femurs and tibias. After removal of all muscle and connective
tissue the bones were placed into 70% EtOH then washed twice in PBS. The bones were
then transferred into a Petri dish which contained 10 ml RPMI 1640 media (Invitrogen
Corporation, Carlsbad, CA). Using sterile scissors both ends of the femur and tibia were
removed and a 25-gauge needle attached to a 3 ml syringe was inserted into either of the
exposed ends and the bone marrow was flushed out with 2 ml of RPMI. This was
repeated for each bone collected. The RPMI was collected in a 15 ml tube and the Petri
dish was rinsed with an additional 5 ml of RPMI, which were also transferred into the 15
ml tube. The tube was centrifuged for 5 min at 1250 rpm. The supernatant was aspirated
and 1 ml of red blood cell lysing buffer (Sigma chemical, St. Louis, MO) was used to
resuspended the pellet and allowed to incubate for 1 minute before adding an additional
14 ml of RPMI 1640. The tube was then centrifuged as before and the pellet was
resuspended in 5 ml of growth media (Growth media consisted of 1/3 J558 supernatant
(collection described above), which contains the GM-CSF and 2/3 RPMI media + 10%
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FBS). The samples were placed into 24 well plates and incubated at 37oC, 5% CO2 for
two days. Feeding of the cells began on day two, 75% of the media in each well was
removed and replaced with fresh growth media. Feedings continued every two days. On
day five, aggregates of DC were sub-cultured by removing them with a sterile Pasteur
pipet and placing them in a new 24 well plate where the feeding continued every two
days.
On day nine, the cells were observed using an inverted microscope. Upon
confirmation that the cells were not contaminated, the following steps were conducted in
the biosaftey cabinet. The loosely adherent cells were removed from the cell culture plate
using a sterile Pasteur pipet and placed in a 15mL conical centrifuge tube. The wells were
then rinsed with 1X trypsin solution and the plate was gently swirled for 1-2 minutes.
RPMI 1640 media + 10% FBS was added to deactivate the trypsin and the cells were
then collected and combined with the loosely adherent cells.
The ability of the DC to take up extracellular material by phagocytosis was
determined by placing the cultured DC with uncoated and protein-coated polystyrene
beads. This was conducted using varying amounts of beads: 0 μl (Sample 1), 5 μl
(Sample 2), and 10 μl (Sample 3) of beads per 1 ml of DC. The phagocytosis assay was
conducted by placing microscope cover slips into 24 well plates and adding DC along
with polystyrene-beads. This culture was incubated in RPMI 1640 media + 10% FBS at
37oC, 5% CO2 for 48 hours. After the incubation period was complete, the DC were
examined at varying magnifications and digital photo documentation was used to record
the results. The loaded cells were also tested in their ability to initiate an immune
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response by activating T-cells via an MHC class I pathway, specifically by testing their
ability to present SIINFEKL to B3Z/LacZ T cell hybridomas.

B3Z Cell Harvesting
T-cell hybridoma cells (B3Z/LacZ clone 28, generously provided by Dr. Nilabh
Shastri, Department of Molecular and Cell Biology, University of California, Berkley)
were obtained in a 1 ml frozen aliquot stored in cryovials. The vials were removed from
liquid nitrogen and placed in 37°C water bath until just before completely thawed. They
were then resuspended in 9 ml complete RPMI-1640 and centrifuged in tabletop
centrifuge at 400 g for 5 minutes. The supernatant was removed, and cells were
resuspended in 10 ml media. This solution was then placed into a Corning 25 cm2 sterile
cell culture flask and incubated at 37°C, 5% CO2 overnight. Cells were monitored three
times per week for growth and percentage confluency. When the cell density was
approximately 90% confluent the cells were passed, if the cell density was less than 90%
and the pH indicator in the media indicated that the media was becoming acidic the
supernatant was aspirated and replaced with fresh complete RPMI media.

B3Z Assay
The B3Z assay was performed in a sterile 96 well plate. The well plate was
prepared by serial dilutions of antigen (microspheres-EVI, microspheres-OVA, or
microspheres-only) using PBS with dilutions from 10 μM to 0 μM. Harvested dendritic
cells and B3Z cells were then added at volumes of 50 μl per well. The plate was
incubated at 37°C, 5% CO2 overnight. The assay also included the addition of Brefeldin
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A (Penicillium brefeldianum) which blocks the function of the Golgi apparatus thus
preventing the processing and presentation of antigen within the DC. This lactone
antibiotic provides a unique opportunity to determine if the protein is being transported
from the interior of the cell to the cells surface via the internal antigen presenting
pathway and thus causing the activation of the B3Z cells. This will help diminish the
likelihood that the activation seen is a direct effect of free protein in solution combining
with the MHC molecules on the T cell surface as opposed to the protein being processed
and presented by the DC.
B3Z cell activation was then determined by the amount of β-galactosidase
produced by the B3Z cells. Luminescent β-gal detection kit II (BD-bioscience) was
removed from 4°C and allowed to warm to room temperature. The 96 well plate was
centrifuged at 400 g for 5 minutes. The media was removed and 200 μl of PBS was
added to each well, the plate was centrifuged as before. The PBS wash was repeated
twice before the addition of the 50 μl of M-PER (Mammalian Protein Extraction
Reagent; Pierce) to each well. The plate was then incubated for 5 minutes at room
temperature while gently shaking. Working solution for the luminescence assay was
prepared (1:50, substrate to buffer) and added to the plate at 150 μl per well. The
supernatant was then removed and placed into a sterile white bottom 96 well plate. The
plate was placed in the GloRunner DXL plate reader (Turner Biosystems) and the
luminescence was taken and saved as an Excel file by the GloRunner DXL computer
program. The results were then graphed and saved for future reference.
An interference assay was also performed in order to determine what effect, if
any, the beads would have on the assay. The assay was done by performing serial
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dilutions of β-galactosidase from a concentration 2x106 mg/ml to 0 mg/ml, beads were
placed in the wells at concentrations equal to those of the B3Z assay and all other steps
were the same as described above. All of the dilutions were done in PBS as well as the
suspension of the beads. This was compared to beads alone as well as pure PBS.
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RESULTS
Verification of Protein Isolation/Purification
The purification and isolation of the recombinant HER-2/neu protein was
confirmed by using SDS-PAGE (Fig.2). The samples loaded onto the gel included the
pre-column proteins and the fraction collected during the affinity chromatography
procedure. The flow thru proteins were analyzed to make sure the protein of interest was
bound to the column, 20 mM fraction was analyzed to make sure the protein of interest
was bound tightly and the 300 mM elution fraction was analyzed to be certain that the
protein of interest was eluted where expected. Additionally, the gel electrophoresis aided
in determining the presence and the purity of the protein. Prior to electrophoresis an
examination of the samples via a standard BCA assay (Pierce) was performed. This
information was used in order to ensure the sample’s protein content did not exceed the
sensitivity of the detection method as specified by manufacturer’s protocol (0.5 μg total
protein per sample). The samples (no more than 25 μl / well) were loaded into the wells
of the 4-12% Bis-Tris Pre-Cast gel. Each sample was loaded into two different wells at
different volumes (10 μl and 20 μl). Staining of the gel was achieved using SimplyBlue
SafeStain (Invitrogen). The staining procedure produced blue bands in the area where
protein was present; the intensity of the band corresponds to the amount of protein
present in each sample. The gel was then dried using DryEase® Mini-Gel Drying System
(Invitrogen). The gel and two pieces of cellophane were soaked in Gel-DryTM Drying
(Invitrogen) solution loaded onto a drying rack and the gel was allowed to dry. The dried
gel was stored at room temperature.
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Upon examination, of the gel it was clear that the flow thru and the 20 mM
imidazole samples contained a great deal of protein but contained very little of our HER2 protein. A band at 58 kDa which corresponds to our protein of interest, HER-2, was
present in the 300 mM imidazole sample. It also showed that there was little to no
additional protein in the 300 mM sample, indicating that the sample was successfully
isolated and purified. This data suggest that our protein was successfully isolated and the
incorporated 6-histidine tail proved to be extremely useful in the isolation procedure.

Isolation / Differentiation of Dendritic Cells
Dendritic cells were obtained from either a mouse spleen or were derived from
mouse bone marrow. The cells were cultured using two different protocols as described
in the methods. The cells isolated from a secondary lymphoid organ were cultured for
only a few hours and did not require an extend growth period, unlike the cells derived
from bone marrow. The DC derived from bone marrow required the addition of
Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) and were cultured for
nine days. There were some differences in the final results between the two procedures
with the most noticeable difference being the number of cells that were produced.
Isolating DC from the spleen is a very efficient way to grow DC, however, the
number of cells produced in this particular procedure was not nearly as great as that seen
with the differentiation of bone marrow. Not only were the number of cells low when
compared to the bone marrow derived DC, but their ability to take up particulate matter
was not very impressive (Fig. 3) when compared to the uptake seen by bone marrow
derived DC.
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The DC isolated from bone marrow showed significant growth of what were
believed to be immature DC. Images were obtained on day five once the cells were
isolated in a new 24-well plate. Figure 4 shows images of cells that were isolated from
bone marrow and it is clear that these cells do not share any phenotypic characteristics
similar to those seen in mature DC. One distinctive example is that there is an apparent
lack of cytoplasmic extensions, which is a key phenotypic feature seen in mature DC
(Fig. 6).
On day nine the cells were once again viewed under a light microscope. An image
was taken to compare the cell’s appearance at day nine to that of cells viewed at day five.
After observing the cells obtained in a variety of slides, it was clear that they all shared
the same appearance as the representative cells shown in Figure 5. It should be noted that
the cells did not appear to share any phenotypic characteristics of mature DC (Fig. 6).
Thus, it may be assumed that the cells observed at day nine are similar, if not identical, to
those observed at day five. The only visible difference between the two samples was an
increase in the number of cells present at day nine (Fig. 5) versus day five (Fig. 4).
On day eleven, after culturing the cells for an additional two days with or without
polystyrene beads, the cells were observed and photographed. Sample 1 (0 μL of beads
per 1 mL of cells) resulted in cells differentiated into mature dendritic cells. This
conclusion was reached due to the phenotypic characteristics of the cells that now
appeared as mature dendritic cells including cytoplasmic extensions. These phenotypic
changes were not present at day five or nine. Figure 6, shows the cytoplasmic membrane
extensions which are a key morphological characteristic of a mature DC.
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In sample 2 (5 μL of protein loaded beads per 1 mL of cells) the cells not only
matured into mature DC, but also phagocytized the polystyrene beads that were present.
These cells also appear to be active at phagocytosis, which is a functional feature of
dendritic cells. In Figure 7, we can clearly identify the beads located within the cells, the
beads within the cell are distinctive and are enclosed within the cells cytoplasmic
membrane. It is also clear that the cells have the long cytoplasmic extensions, which
indicates that the cells have differentiated from an immature state to a mature state.
In sample 3 (10 μL of protein loaded beads per 1 mL of cells) the cells also
differentiated from an immature state to a mature state, which can be seen in figure 8.
These cells were also able to phagocytize the polystyrene beads. However, it did not
appear that these cells were able to phagocytize the same number of beads as the cells in
sample 2. In comparing sample 3 to sample 2, a great deal of bead agglutination had
occurred in sample 3 which did not occur in sample 2. Figure 8 clearly illustrates the
differentiation of the cells, the phagocytosis of the beads by the mature DC, and the
agglutination of the beads. The microsphere agglutination resulted in particles that were
possibly too large for DC to phagocytize and thus fewer microspheres were available to
be phagocytized. This may indicate a problem with the concentration of beads used. It
was also observed that the cells in sample 3 did not differentiate to the extent that was
observed in sample 2. The amount of cell differentiation observed in sample 3 was
comparable to that seen in sample 1 (Fig. 6, 8). This could indicate that the cells require a
certain threshold of particulate matter to phagocytize that was not present in sample 3 as
a result of microsphere agglutination.

25

It was apparent that the DC prepared from bone marrow appeared to have a much
greater ability in taking up particulate matter when compared to the DC isolated from the
spleen. This was seen in each of the each of the samples, however, more particulate
matter was up taken in sample 2 (5μL of protein loaded beads per 1mL of cells) than in
sample 3 (10μL of protein loaded beads per 1mL of cells). However, one of the most
interesting results was from the B3Z assay.

B3Z Assay
The B3Z assay provided a very useful and practical way to test the DC ability to
initiate a cytotoxic response in vitro. The activation of the B3Z/Lac-Z cells, which were
only able to be activated via the MHC class I pathway, resulting in the production of
β-galactosidase provided a convenient way to measure activation of the T-cell hybridoma
(Shastri & Gonzalez, 1993).
The first question to be addressed was what problem, if any, would be caused by
the presence of the phagocytized microspheres while luminescence was being measured
in the luminometer. To answer this question an interference assay was performed (Fig. 9).
Using known concentrations of β-galatosidase and varying concentrations of beads in
PBS as well as PBS alone any possible interference due to the beads was determined. The
assay demonstrated that the beads did not cause any interference with the assay and also
provided insight into the sensitivity of the assay (Fig. 9). Based on the results of this
assay the lowest concentration of β-galatosidase detectable using this assay was
approximately 1.82x10-7 μΜ. Once it was confirmed that the beads did not appear to
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have a negative effect on the luminescence values, protein coated beads were cultured
with DC derived from bone marrow as well as DC isolated from the spleen.
The bone marrow derived DC (BMDC) had an extraordinary ability to
phagocytize the protein coated beads. The number of bone marrow derived DC appeared
to be much greater in number when compared to the DC isolated from the spleen.
However, the ability of BMDC to activate the B3Z cells following exposure to protein
coated beads was only slightly improved when compared to DC isolated from the spleen
which had been pulsed with soluble protein (Fig. 10). The data also demonstrated
increased activation of B3Z cells, when BMDC were pulsed with protein coated beads
versus soluble protein (Fig. 10). Activation of B3Z cells was greater when the BMDC
were pulsed with protein coated beads than when they were pulsed with soluble protein: a
lower concentration of protein coated beads achieved greater B3Z cell activation
compared to soluble protein. The amount of activation appeared to drop at higher
concentrations of protein in the BMDC. This was apparent in both of the samples that
were pulsed with protein coated beads; the beads which possibly assisted in the increased
activation of B3Z β-gal production could have also been harmful to the DC when higher
concentrations of protein coated beads were used. In contrast we found that all the DC
pulsed with soluble protein still had an increasing activation trend (Fig. 10). In the assays
were the DC where pulsed specifically with EVI coated beads or OVA coated beads there
was a great increase in the ability to activate the B3Z cells seen at lower concentrations
however their ability to maintain the activation decreased at the highest concentration for
EVI and at the two higher concentrations for OVA (Fig. 10). The data also demonstrate
that the cells pulsed with EVI coated beads resulted in an overall activation almost
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equally as great as that seen with the OVA coated beads. However, when the activation
of the B3Z cells is compared to the concentration of the protein it was apparent that the
EVI coated beads caused a greater response at lower concentrations, specifically at the 5
μM EVI concentration (Fig. 10).
The data clearly demonstrate that there was an apparent difference in the
activation of the B3Z cells by BMDC pulsed with either EVI coated beads or OVA
coated beads when compared to soluble protein. The difference in activation was even
more apparent when using DC isolated from murine spleen (Fig.11-14). These DC were
loaded with protein-coated beads and compared to soluble protein. Dendritic cells
isolated from the spleen were not very aggressive in phagocytizing the protein-coated
beads. Regardless of the cells decreased ability to phagocytize particulate matter their
ability to activate the B3Z cells was far greater than the BMDC. This was especially true
with the EVI coated beads and the OVA coated beads when compared to soluble protein
(Fig. 12). It is interesting to note that protein coated beads resulted in activation of the
B3Z cells at a much lower concentrations versus the higher concentrations required to
activate the B3Z cells when the proteins were in their soluble form. Activation resulting
by spleen derived DC loaded with OVA coated beads was seen at a concentration of 1.56
μM, by far one of the lowest concentrations that resulted in activation of B3Z cells seen
during the course of this study while using OVA as activating agent. Typically, when DC
were loaded with soluble OVA activation of B3Z cells was usually seen at concentrations
of approximately 25 μM. The DC appeared to reach a maximum capacity in their ability
to activate B3Z cells, as it was observed at the higher concentrations (25, 50 and 100 μM)
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of the OVA-beads loaded DC, concentrations that there was no greater degree of
stimulation (Fig. 11 & 13).
The spleen derived DC loaded with EVI coated beads resulted in an increased
activation of the B3Z cells which was initiated by an EVI-bead concentration of 0.156
μM (Fig. 12 &14). It was consistently seen throughout the course of the project that the
lowest concentration of EVI coated beads was sufficient to initiate activation of B3Z cells
to a greater extent than soluble protein alone. The data clearly demonstrates how much
more effective the EVI-bead combination was to activate the B3Z cells. When the
activation of EVI-bead combination was compared to soluble EVI alone it is clear that it
combining the EVI with the beads provides a way to activate B3Z cells with greater
effectiveness. It was interesting to note that the activation of the B3Z cells with 10 μM of
EVI-beads resulted in an activation of the B3Z cells which was approximately half that
seen with 100 μM OVA-beads (Fig. 11 & 12). The data also demonstrated that the
activation could possibly continue to rise but eventually, like the results seen with the DC
loaded with OVA-beads combination, a plateau would likely occur, thus, indicating that
there is a limiting factor that is occurring either with or within the cells (Fig. 13).
Comparing mature spleen derived DC pulsed with soluble EVI and EVI coated beads and
treated samples with Brefeldin A, provided data suggesting that the activation of B3Z
cells was in fact due to DC processing and presenting antigen via MHC I pathway (Fig.
14). Thus, B3Z cell production of β-galactosidase could only be due to B3Z cells being
activated by DC and not by free protein in solution combing with the MHC molecules on
the B3Z cells surface.
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DISCUSSION
It has been shown that dendritic cells are extremely effective at capturing,
processing and presenting antigen. Dendritic cells incorporated into immunotherapies
may provide a useful and novel treatment against specific cancers. Through the use of
known tumor associated antigens, such as HER-2/neu, a specific therapy can be
developed against tumors which overexpress a specific protein or proteins.
In developing this study it was imperative to integrate methods which would (1)
produce a great deal of protein that could be isolated and purified, (2) a way to make the
protein more antigenic, (3) determine if the dendritic cells were presenting the antigen via
a class I MHC molecule. The isolation and purification of EVI was clearly achieved by
the design of the protein. Incorporating the EVI-DNA into Rosetta Escherichia coli and
allowing them to grow, produce and store the EVI-protein in inclusion bodies allowed for
production of a large amount of protein which could be isolated and purified. The integral
six histidine tail allowed for the protein to isolated using Ni-based affinity
chromatography thus allowing for isolation of EVI with a great deal of specificity.
Attaching the protein to the polystyrene microspheres facilitated the increase in
antigenicity. Pulsing DC with beads coated with EVI provided insight into exactly how
many beads would be taken up, but it also allowed for a greater amount of protein to be
introduced into the DC for processing. This in turn allowed for a direct comparison
between immature and mature DC ability to take up particulate matter, something that
could not have be accomplished without the polystyrene beads. It was very clear that the
beads not only facilitated a greater amount of protein to be loaded into the DC but also
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demonstrated that immature DC ability to take up particulate matter far exceed that seen
with the mature DC.
Determining the presentation of the antigen was achieved by performing a B3Z
assay. The assay incorporates DC loaded at varying concentrations and a T-cell
hybridoma, the B3Z cell, which recognizes the SIINFEKL (amino acid residues 257-264
of chicken ovalbumin) epitope which was incorporated into the design of EVI. The
activation of the B3Z cells was measured by the amount of β-galactosidase produced by
the B3Z cells (Shastri & Gonzalez, 1993). The greater the activation the greater the
amount of β-galactosidase produced. It was very interesting to observe that the mature
DC which had been loaded with EVI coated beads were able to activate the B3Z cells to a
greater extent when compared to mature DC loaded with soluble EVI and immature cells
loaded with EVI coated beads. Given that SIINFEKL is found within ovalbumin,
ovalbumin was used as a positive control in a soluble form as well as bound to
polystyrene beads. The OVA coated beads were compared to soluble OVA which were
pulsed onto immature and mature DC. When comparing the β-galactosidase production
by B3Z cells, mature DC were able to produce levels that were detectable at far lower
concentrations of OVA when OVA was bound to the polystyrene beads compared to
immature DC. The immature DC were not as effective in demonstrating a difference in
activating B3Z cells when pulsed with either soluble OVA or OVA coated beads. For
mature DC it was clear that the OVA coated beads were able to elicit a greater activation
of B3Z cells than soluble OVA alone. This data implied that mature DC provided
superior activation of the B3Z cells when the DC were pulsed with OVA coated beads.
While the immature DC were far more effective in the uptake of the OVA-albumin
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coated beads, their ability to activate B3Z cells was mediocre at best when compared to
the mature DC. Activation of B3Z cells by mature and immature DC loaded with soluble
EVI and EVI coated beads was also tested. The data from these experiments appears to
coincide with the results gathered from the OVA experiments. The activation of B3Z
cells by mature DC was far greater when the DC were pulsed with EVI coated beads.
Mature DC loaded with soluble EVI provided greater activation of B3Z cells than the
immature cells loaded with either soluble EVI or EVI coated beads.
There may be a few possible explanations for the lack of B3Z cell activation by
the immature DC. Given that immature DC were far greater at taking up particulate
matter when compared to mature DC one might expect that immature DC would elicit a
greater activation of B3Z cells, however, this was not the case. The fact that immature
DC took up so many of the antigen coated beads could have posed a problem. The
polystyrene beads are not biodegradable this may have caused an obstruction within
cellular compartments of the DC, particularly within the Golgi apparatus. Causing a
blockage within the Golgi apparatus would result in prevention of packaging and
transportation of antigen epitopes to the cell’s surface. In addition to the possible
obstruction of the Golgi apparatus, immature DC display low amounts of MHC I and
MHC II, specifically the class I MHC. This may have resulted in decreased activation of
B3Z cells. It is essential to note that the results observed with the immature DC
experiments provide vital insight into the importance of maturing DC prior to
immunization. However, it is also imperative to mention that in vivo it is possible for DC
to migrate to secondary lymphoid organs and undergo further maturation. Thus, despite
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the recent in vitro observations we cannot dismiss immature DC as important initiators of
an immune response.
The importance of maturing the DC was certainly confirmed by the in vitro
studies. These studies demonstrated how effective mature DC were in initiating the
activation of the B3Z T-cell hybridoma. In addition to maturing DC, it was also evident
that pulsing mature DC with protein-coated beads resulted in increased activation of the
B3Z cells possibly due to a greater amount of protein (antigen) entering the cell. The
levels of β-galactosidase observed were not only much higher but they also detected
antigen at much lower concentrations in the groups where the mature DC were pulsed
with the OVA and EVI coated bead. This indicates that a greater amount of protein was
actually being taken up and processed by the cells, when the protein was bound to the
polystyrene beads. These results show that the antigenicity of the protein was greater
when bound to the polystyrene beads than in its soluble form. It is important to note that
the negative effect the beads had on the immature DC was not seen in the mature DC,
possibly due to the lesser number of beads which were taken up by the mature DC.
However, the toxic effects that were observed in the immature DC experiments may be
overcome by binding antigens to bio-degradable beads.
In conclusion, the maturity of dendritic cells does appear to play a crucial role in
developing an antigen specific immune response. In addition, the method of delivering
the antigens to APC seems to be just as important. By binding antigens of interest to
particulate matter, such as polystyrene beads or bio-degradable beads, the antigenicity
seems to increase dramatically. This increase in antigenicity may in turn trigger an
immune response against a tumor-associated antigen of interest, such as HER-2/neu. This
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is just one example as to how manipulation of the immune system may be able to elicit a
specific and possibly an extremely effective immune response against specific cell
surface antigens which are over-expressed in certain malignancies, such as HER-2/neu
positive breast cancer.
Immunotherapy is most certainly a novel concept which may be patient specific
and may provide patients with an adjuvant treatment which may work in conjunction
with the conventional therapy. Immunotherapy may have far less side effects when
compared to the current standard of care; however, there are still many questions that
need to be answered before each malignancy has it own specific and effective treatment.
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Figure 1: Representative affinity chromatography data indicating the results of a complete FPLC
protein isolation. The first two peaks indicate the flow through, protein loaded onto the column that
did not bind. The next peak indicates the 20 mM imidazole fraction which will remove the protein
that is loosely adhered to the column. The final peak, within the yellow outline, indicates the elution
of the protein of interest. Each of the red lines in the bottom of the figure indicates a 300 mM
imidazole elution fraction that was collected. These fractions were then combined and the results are
confirmed via SDS-PAGE.
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Figure 2: SDS-PAGE was used to confirm the presence of the protein of interest, EVI, within
the 300 mM imidazole fraction. The gel demonstrates that the protein of interest was found
within the pre-column fraction and only a small amount within the flow thru. There was no
EVI detected within the 20mM fraction, however, a large amount of the 58 KD protein (EVI)
was detected in the 300 mM fraction, thus confirming the results of the FPLC absorption
spectra as well as indicating that we were able to purify our protein from nearly all other
proteins observed in the pre-column sample.
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Figure 3: Image of a mature spleen-derived dendritic cell. The image was obtained at 1000x.
The sample was obtained after a brief two culture preparation. This sample conatined 1 mL
of spleen derived dendritic cells, with 5 μL of beads added to the sample. It is important to
note the phagocytosis of polystyrene beads, which is a functional characteristic of dendritic
cells. Spleen derived DC also display phenotypic characteristics which are similar to those
seen in mature dendritic cells. This image demonstrates that cells are functional, however,
the number of cells is much lower than what was seen when dendritic cells were generated
from murine bone marrow.
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Figure 4: Image of immature bone marrow derived dendritic cells obtained at 400x. The
sample was obtained after five day subculture preparation. It is important to note that the
cells share no phenotypic characteristics similar to those seen in mature dendritic cells.
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Figure 5: Image of bone marrow derived immature dendritic cells obtained at 1000x. The
sample was obtained after a nine day subculture preparation. It is important to note that the
cells have not developed phenotypic characteristics similar to those seen in mature dendritic
cells.
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Figure 6: Image of bone marrow derived mature dendritic cells obtained at 1000x. The
sample was obtained after the eleventh day subculture preparation, of 1mL of dendritic
cells, with no beads added to the sample. The BMDC have now developed phenotypic
characteristics similar to those seen in mature dendritic cells, which were not observed in the
cells at day five or day nine.
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Figure 7: Image of mature dendritic cells obtained at 1000x. The sample was obtained after
the eleventh day subculture preparation, of 1 mL of dendritic cells, with 5 μL of beads added
to the sample. It is important to note the phagocytosis of polystyrene beads, which is a
functional characteristic of dendritic cells, as well as, phenotypic characteristics which
similar to those seen in mature dendritic cells. The phenotypic characteristics were not
observed in the cells at day five or day nine.
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Figure 8: Image of mature Dendritic cells obtained at 1000x. The sample was obtained after
the eleventh day subculture preparation, of 1 mL of dendritic cells, with 10 μL of beads
added to the sample. It is important to note the phagocytosis of the polystyrene beads, which
is a functional characteristic of dendritic cells, as well as phenotypic characteristics which
are similar to those seen in mature dendritic cells. In this sample it must be noted that there
was an increased amount of bead agglutination. The phenotypic characteristics were not
observed in the cells at day five or day nine.
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Microsphere Interference assay
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Figure 9: An interference assay was performed in order to determine if the polystyrene beads would
have a negative effect when gathering data via a microplate luminometer. In addition to determining
that the beads had the same effect as PBS, thus no negative effect on the luminescence, an assay
detection range was also determined. This was of critical importance because it demonstrated the
lowest amount of β-galactosidase that needed to be produced by the B3Z cells to be detected in our
assay system.
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B3Z Assay:
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Figure 10: Comparing B3Z cell activation by bone marrow derived dendritic cells (BMD) and spleen
derived dendritic cells (S). B3Z CD8+ T-cell hybridoma clone specific for the OVA SIINFEKL
peptide (amino acids 257-267) which express the LacZ gene under the control of the interleukin-2
promoter was used to determine activation via MHC-I by DC isolated from murine spleen or derived
from murine bone marrow. A direct comparison of DC isolated from spleen to DC derived from bone
marrow where the DC were loaded with OVA, OVA-coated beads, EVI, EVI-coated beads, beads
without any protein, or pulsed with EVI-rGM. Activation of the B3Z cells was determined by
measuring LacZ activity after incubating the cells with loaded DC for 12-24 hours. The data
illustrates that DC isolated from spleen provided greater activation of T-cell when compared to DC
derived from bone marrow, this activation was even more apparent when the protein was attached to
the polystyrene beads.
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B3Z Assay:
Measuring LacZ gene Activation of B3Z cells by
Dendritic Cells isolated from Murine Spleen
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Figure 11: B3Z CD8+ T-cell hybridoma clone specific for the OVA SIINFEKL peptide (amino acids
257-267) which express the LacZ gene under the control of the interleukin-2 promoter was used to
determine activation via MHC-I by DC isolated from murine spleen. Dendritic cells were been loaded
with OVA, OVA-coated beads, EVI, EVI-coated beads, or beads without any protein. Activation of
the B3Z cells was determined by measuring LacZ activity after incubating the cells with loaded DC
for 12-24 hours.
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B3Z Assay:
Measuring LacZ gene Activation of B3Z cells by
Dendritic Cells isolated from Murine Spleen
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Figure 12: B3Z CD8+ T-cell hybridoma clone specific for the OVA SIINFEKL peptide (amino acids
257-267 of ovalbumin) which express the LacZ gene under the control for the interlukin-2 promoter
was used to determine activation via MHC-I by DC isolated from murine spleen. Dendritic cells were
loaded with EVI, or EVI-coated beads. Activation of the B3Z cells was determined by measuring the
LacZ activity after incubating the cells with loaded DC for 12-24 hours.

48

B3Z Assay:
Direct Comparison of spleenocytes treated and untreated with Brefeldin A.
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Figure 13: B3Z Assay Results Using DC isolated from murine spleen. Dendritic cells have been
loaded with one of the indicated proteins, or the protein-coated beads. The cells were also treated
with Brefeldin A (5 μg/ml) in order to confirm that the activation seen was a result of a protein
presented via an MHC-I pathway and that the activation of the B3Z cells had not resulted from free
floating protein.
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B3Z Assay:
Direct Comparison of spleenocytes treated and untreated with Brefeldin A.
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Figure 14: B3Z cell activation using DC isolated from murine spleen. Dendritic cells have been
loaded with EVI, or EVI-coated beads. Activation of the B3Z cells was determined by the amount of
β-galactosidase produced by the B3Z cells. The cells were also treated with Brefeldin A (5 μg/ml) in
order to confirm that the activation seen was a result of protein presented via an MHC-I pathway by
DC and that activation of the B3Z cells had not resulted from free floating protein binding with cell
surface MHC on the B3Z cells.
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APPENDIX A:
LETTER OF APPROVAL FOR THE USE OF VERTEBRATE ANIMALS IN
RESEARCH FROM NORTHERN MICHIGAN UNIVERSITY’S DEAN OF
GRADUATE STUDIES
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